NICE TAs

18/08/2020

TA127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis

18/08/2020

TA134: Infliximab for the treatment of adults with psoriasis

18/08/2020

TA153: Entecavir for the treatment of chronic hepatitis B

18/08/2020

TA278: Omalizumab for treating severe persistent allergic asthma (replaced TA133)

18/08/2020

TA235: Mifamurtide for the treatment of osteosarcoma

18/08/2020

TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis

18/08/2020

TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia

18/08/2020

TA191: Capecitabine for the treatment of advanced gastric cancer

18/08/2020

TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (replaced TA175, terminated appraisal)

18/08/2020

TA218: Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

18/08/2020

TA247: Tocilizumab for the treatment of rheumatoid arthritis (this has been partially replaced by TA375 - only covers DMARDs, not TNF inhibitors)

18/08/2020

TA177: Alitretinoin for the treatment of severe chronic hand eczema

13/08/2020

TA220: Golimumab for the treatment of psoriatic arthritis

13/08/2020

TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (replaced TA42)

13/08/2020

NG131: Prostate cancer: diagnosis and management

13/08/2020

TA197: Dronedarone for the treatment of non-permanent atrial fibrillation

13/08/2020

TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer

13/08/2020

TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia

13/08/2020

TA432: Everolimus for advanced renal cell carcinoma after previous treatment (replaced TA219)

13/08/2020

TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer